ClinicalTrials.gg
Not yet recruitingNCT07847411Updated Sep 29, 2026

Study of Velaglucerase Beta ERT in Children With Gaucher Disease

A Phase 3 interventional study of Velaglucerase beta in Gaucher Disease, Gaucher Disease Type 1 and Gaucher Disease Type 3, sponsored by CANbridge Life Sciences Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by CANbridge Life Sciences Ltd. · Phase 3, Interventional, and Treatment

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
2 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Gaucher Disease with a site in China — 7 open to participants now, 9 under way, 2 of them phase 3. Gaucher Disease · China.

Planned enrollment
8th of 12
10 · median 12
Started
2026
with 1 other
Phase 3
4 of 13
1 open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
CANbridge Life Sciences Ltd.

Among the 13 studies in Gaucher Disease with a site in China, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 13th registered.

Gaucher Disease

177 studies on the registry are indexed under Gaucher Disease; 41 are open to participants now.

Browse Gaucher Disease studies →

Open to participants now

7 of the 13 studies in Gaucher Disease with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 26 Gaucher Disease studies recruiting now, 11 (42%) set no upper age limit and 11 (42%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 2 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Gaucher Disease with a site in China, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, open-label, single-arm study to evaluate the safety, efficacy, PK, PD, and immunogenicity of velaglucerase beta in untreated children with GD1 or GD3 for 39 weeks.

03

Conditions studied

  • Gaucher Disease
  • Gaucher Disease Type 1
  • Gaucher Disease Type 3

Browse trials for

Keywords

  • Gaucher disease
  • ERT
  • CAN103
  • Velaglucerase beta
  • Gaurunning
04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has a documented diagnosis of GD1 or GD3 according to the diagnostic criteria of the Expert Consensus on the Diagnosis and Treatment of Gaucher Disease in Chinese Children 2021;
  2. Written provided by the subject's parent/legally authorized representative;
  3. Subject is less than 12 years of age;
  4. Subject has GD-related splenomegaly, defined as at least 2 to 3 cm below the left costal margin by palpation, and one or more of the following:

    1. GD-related anemia, with a decrease of ≥1 g/dL in concentration below the lower limit of normal for age of the central laboratory; or
    2. GD-related hepatomegaly by palpation; or
    3. GD-related thrombocytopenia, with a count \< 100 × 10\^9/L;
  5. Subject has not received ERT or SRT for at least 3 months prior to screening; Female subjects of childbearing age have a negative serum pregnancy test during screening.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with drugs (including ambroxol) within 30 days or 5 half-lives, whichever is longer, prior to screening;
  2. Subjects have received erythropoietin, whole blood transfusion or transfusion of red blood cells, or long-term (continuous treatment for more than 3 months) systemic 3 months prior to screening; or received a transfusion within 1 month prior to screening;
  3. Subject has non-Gaucher disease-related anemia (such as due to iron, folic acid, and/or vitamin B12 deficiency or infection/immune-mediated reasons);
  4. Subject has had a prior hepatectomy and/or splenectomy (including partial liver and/or splenectomy) or plans to have a hepatectomy and/or splenectomy (including partial liver and/or splenectomy) during the study;
  5. Subject has received organ transplantation, including hematopoietic stem cell transplantation;
  6. Subject has had a history of Grade 3 or above infusion-related reaction or reaction to imiglucerase or other ERTs (approved or experimental).
  7. Injection with a within 30 days of the first study dose.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    velaglucerase beta 60 U/kg

    This is a single-arm study. All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks.

    Drug: Velaglucerase beta

Interventions

  • DrugVelaglucerase beta

    All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks with two weeks of follow-up through Week 39 (9 months).

06

What researchers measure

Primary outcomes

  1. Primary Endpoints

    Incidence and number of TEAE, characterized by type, severity, seriousness (SAE), and relatedness to velaglucerase

    Time frame: From Baseline to Week 39

  2. Mean percent change in MN spleen volume

    Normal spleen volume = 0.2% body weight. Multiples of normal (MN) spleen volume= actual MRI testing volume / normal spleen volume

    Time frame: From Baseline to Week 39

Secondary outcomes

  1. Mean change in hemoglobin concentration (g/dL)

    Time frame: From baseline to Week 39

  2. Mean percent change in MN liver volume

    Normal liver volume = 2.5% body weight. Multiples of normal (MN) liver volume= actual MRI testing volume / normal liver volume

    Time frame: From Baseline to Week 39

  3. Mean percent change in platelet count ( 10^9/L)

    Time frame: From Baseline to Week 39

  4. Mean change in height Z-score

    Time frame: From Baseline to Week 39

  5. Mean change in weight Z-score

    Time frame: From Baseline to Week 39

07

Study locations

1 site
  • Room 202, 2nd Floor, 780 Cailun Road, Pilot Free Trade Zone
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: Yes — only IPD used in the results publication

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months and ending 3 years after the publication of results

Access criteria: The criteria that must be met the types of analyses that qualify for data sharing. A proposal that describes planned analyses must be submitted.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Feb 2028, 17 months later.

Of 11 phase 3 interventional studies under Gaucher Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2026
First posted
Sep 29, 2026
StartEst.
Sep 16, 2026
Primary completionEst.
Feb 25, 2028
CompletionEst.
Feb 25, 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847411
Lead sponsor
CANbridge Life Sciences Ltd.
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Sep 16, 2026 (estimated)
Primary completion
Feb 25, 2028 (estimated)
Completion
Feb 25, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Charlene Song
Contact
xiaoling.song@canbridgepharma.com
+86 18817946880
Amelia Zhou
Contact
feng.zhou@canrbdigepharma.com
+86 18016327369

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion